These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation. Unzue A; Dong J; Lafleur K; Zhao H; Frugier E; Caflisch A; Nevado C J Med Chem; 2014 Aug; 57(15):6834-44. PubMed ID: 25076195 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2. Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832 [TBL] [Abstract][Full Text] [Related]
4. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. Zhao H; Huang D; Caflisch A ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132 [TBL] [Abstract][Full Text] [Related]
6. Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]thieno[3,2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. Vidaillac C; Guillon J; Moreau S; Arpin C; Lagardère A; Larrouture S; Dallemagne P; Caignard DH; Quentin C; Jarry C J Enzyme Inhib Med Chem; 2007 Oct; 22(5):620-31. PubMed ID: 18035830 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives as potential inhibitors of Akt kinase. Desplat V; Geneste A; Begorre MA; Fabre SB; Brajot S; Massip S; Thiolat D; Mossalayi D; Jarry C; Guillon J J Enzyme Inhib Med Chem; 2008 Oct; 23(5):648-58. PubMed ID: 18821254 [TBL] [Abstract][Full Text] [Related]
8. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase. Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384 [TBL] [Abstract][Full Text] [Related]
9. Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo. Liu QQ; Lu K; Zhu HM; Kong SL; Yuan JM; Zhang GH; Chen NY; Gu CX; Pan CX; Mo DL; Su GF Eur J Med Chem; 2019 Mar; 165():293-308. PubMed ID: 30685528 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II. Desplat V; Moreau S; Gay A; Fabre SB; Thiolat D; Massip S; Macky G; Godde F; Mossalayi D; Jarry C; Guillon J J Enzyme Inhib Med Chem; 2010 Apr; 25(2):204-15. PubMed ID: 20222763 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421 [TBL] [Abstract][Full Text] [Related]
12. Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors. Musumeci F; Sanna M; Greco C; Giacchello I; Fallacara AL; Amato R; Schenone S Expert Opin Ther Pat; 2017 Dec; 27(12):1305-1318. PubMed ID: 28705083 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme. Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549 [TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors. Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors. Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040 [TBL] [Abstract][Full Text] [Related]